{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14"],"submitter":["Harman T"],"pubmed_abstract":["<b>Background:</b> T-type Ca<sup>2+</sup> channels (Ca<sub>v</sub>3) represent emerging therapeutic targets for a range of neurological disorders, including epilepsy and pain. To aid the development and optimisation of new therapeutics, there is a need to identify novel chemical entities which act at these ion channels. A number of synthetic cannabinoid receptor agonists (SCRAs) have been found to exhibit activity at T-type channels, suggesting that cannabinoids may provide convenient chemical scaffolds on which to design novel Ca<sub>v</sub>3 inhibitors. However, activity at cannabinoid type 1 (CB<sub>1</sub>) receptors can be problematic because of central and peripheral toxicities associated with potent SCRAs. The putative SCRA MEPIRAPIM and its analogues were recently identified as Ca<"],"journal":["Frontiers in physiology"],"pagination":["1086243"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10110893"],"repository":["biostudies-literature"],"pubmed_title":["MEPIRAPIM-derived synthetic cannabinoids inhibit T-type calcium channels with divergent effects on seizures in rodent models of epilepsy."],"pmcid":["PMC10110893"],"pubmed_authors":["Howland JG","Snutch TP","Ametovski A","Banister SD","Greba Q","Harman T","Arnold JC","Kevin RC","Udoh M","McElroy DL","Anderson LL","Doohan PT","Markham J","Bladen C","McGregor IS","Laprairie RB"],"additional_accession":[]},"is_claimable":false,"name":"MEPIRAPIM-derived synthetic cannabinoids inhibit T-type calcium channels with divergent effects on seizures in rodent models of epilepsy.","description":"<b>Background:</b> T-type Ca<sup>2+</sup> channels (Ca<sub>v</sub>3) represent emerging therapeutic targets for a range of neurological disorders, including epilepsy and pain. To aid the development and optimisation of new therapeutics, there is a need to identify novel chemical entities which act at these ion channels. A number of synthetic cannabinoid receptor agonists (SCRAs) have been found to exhibit activity at T-type channels, suggesting that cannabinoids may provide convenient chemical scaffolds on which to design novel Ca<sub>v</sub>3 inhibitors. However, activity at cannabinoid type 1 (CB<sub>1</sub>) receptors can be problematic because of central and peripheral toxicities associated with potent SCRAs. The putative SCRA MEPIRAPIM and its analogues were recently identified as Ca<","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023","modification":"2026-05-28T17:58:51.603Z","creation":"2024-12-03T15:59:54.595Z"},"accession":"S-EPMC10110893","cross_references":{"pubmed":["37082241"],"doi":["10.3389/fphys.2023.1086243"]}}